Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Payables: 2011-2025

Historic Payables for RedHill Biopharma (RDHL) over the last 15 years, with Jun 2025 value amounting to $835,000.

  • RedHill Biopharma's Payables fell 56.33% to $835,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $7.2 million, marking a year-over-year decrease of 43.22%. This contributed to the annual value of $1.2 million for FY2024, which is 64.37% down from last year.
  • As of Q2 2025, RedHill Biopharma's Payables stood at $835,000, which was down 28.51% from $1.2 million recorded in Q4 2024.
  • RedHill Biopharma's Payables' 5-year high stood at $119.4 million during Q4 2022, with a 5-year trough of $835,000 in Q2 2025.
  • For the 3-year period, RedHill Biopharma's Payables averaged around $2.4 million, with its median value being $2.5 million (2023).
  • As far as peak fluctuations go, RedHill Biopharma's Payables increased by 25.36% in 2022, and later tumbled by 97.26% in 2023.
  • RedHill Biopharma's Payables (MRQ) stood at $95.3 million in 2021, then grew by 25.36% to $119.4 million in 2022, then crashed by 97.26% to $3.3 million in 2023, then plummeted by 64.37% to $1.2 million in 2024, then fell by 28.51% to $835,000 in 2025.
  • Its Payables was $835,000 in Q2 2025, compared to $1.2 million in Q4 2024 and $1.9 million in Q2 2024.